| Title |
Use of β-Blockers and the Risk of Hip/Femur Fracture in the United Kingdom and The Netherlands
|
|---|---|
| Published in |
Calcified Tissue International, February 2007
|
| DOI | 10.1007/s00223-006-0213-1 |
| Pubmed ID | |
| Authors |
F. de Vries, P. C. Souverein, C. Cooper, H. G. M. Leufkens, T. P. van Staa |
| Abstract |
Data from in vivo studies have indicated a role for beta-blockers in the prevention of bone loss. Some epidemiological studies have found protective effects of beta-blockers on fracture risk. However, there is limited information on the association with cumulative dose and type of beta-blockers used. We conducted two case-control studies using data from the UK General Practice Research Database (GPRD) and the Dutch PHARMO Record Linkage System (RLS). Cases were patients with a first hip or femur fracture; controls were individually matched on practice/region, gender, year of birth, and calendar time. Current use of beta-blockers was defined as a prescription in 90 days before the index date. We adjusted for medical conditions and drugs associated with falling or bone mineral density. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression analysis. The study population included 22,247 cases and controls in the GPRD and 6,763 cases and 26,341 controls in the PHARMO RLS. Current use of beta-blockers was associated with a reduced risk of hip/femur fracture in both the GPRD (adjusted OR = 0.82, 95% CI 0.74-0.91) and PHARMO RLS (adjusted OR = 0.87, 95% CI 0.80-0.95) study populations. However, this reduction of risk was not associated with cumulative dose, lipophilicity, or receptor selectivity of beta-blockers. The protective effect of beta-blockers was only present among patients with a history of use of other antihypertensive agents (GPRD adjusted OR = 0.72, 95% CI 0.64-0.83; PHARMO RLS adjusted OR = 0.76, 95% CI 0.67-0.86) but not in patients using beta-blockers only (GPRD adjusted OR = 0.97, 95% CI 0.82-1.14; PHARMO RLS adjusted OR = 1.01, 95% CI 0.90-1.14). Also, in patients with a history of use of other antihypertensive agents, no dose-response relationship with beta-blocker use was found. The effect was constant with cumulative dose and the OR was below 1.0 even among patients who just started treatment with beta-blockers. As the mechanism by which beta-blockers could influence bone mineral density is likely to need some time to exert a clinically relevant effect, all these finding suggests that the association between beta-blockers and fracture risk is not causal. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Unknown | 53 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 20% |
| Researcher | 11 | 20% |
| Student > Master | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Professor | 3 | 6% |
| Other | 10 | 19% |
| Unknown | 10 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Agricultural and Biological Sciences | 4 | 7% |
| Economics, Econometrics and Finance | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 15 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2015.
All research outputs
#7,472,296
of 22,844,985 outputs
Outputs from Calcified Tissue International
#544
of 1,760 outputs
Outputs of similar age
#43,876
of 160,929 outputs
Outputs of similar age from Calcified Tissue International
#5
of 7 outputs
Altmetric has tracked 22,844,985 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,760 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,929 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.